319473-70-6 Usage
Derivative of benzamide
A modified version of the benzamide compound, which is a basic structural unit consisting of a benzene ring connected to an amide group (-CONH2).
Contains two amino groups
Amino groups (-NH2) are functional groups present in the molecule, contributing to its reactivity and ability to form various chemical bonds.
Contains a methyl group
A methyl group (-CH3) is a small alkyl group derived from methane, adding steric hindrance and affecting the compound's properties.
Widely used in organic synthesis and medicinal chemistry
The compound serves as an intermediate in the production of pharmaceuticals and other organic compounds, making it a valuable building block in these fields.
Potential biological and pharmacological properties
The compound has been studied for its possible effects on living organisms and its potential use in medicine, including its activity as an anticancer agent.
Activity as an anticancer agent
The compound has shown promise in inhibiting the growth and spread of cancer cells, making it a potential candidate for cancer treatment.
Valuable building block for the synthesis of complex molecules
Due to its unique structure and properties, the compound can be used to create a variety of complex molecules, which may have applications in pharmaceutical and medical research.
Check Digit Verification of cas no
The CAS Registry Mumber 319473-70-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,9,4,7 and 3 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 319473-70:
(8*3)+(7*1)+(6*9)+(5*4)+(4*7)+(3*3)+(2*7)+(1*0)=156
156 % 10 = 6
So 319473-70-6 is a valid CAS Registry Number.
319473-70-6Relevant articles and documents
Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer
Elkins, Jonathan M.,Fala, Angela M.,Massirer, Katlin B.,Pennicott, Lewis E.,Reuillon, Tristan D.,Scott, Fiona,Ward, Simon E.
supporting information, (2020/02/27)
Kinases are signalling proteins which have proven to be successful targets for the treatment of a variety of diseases, predominantly in cancers. However, only a small proportion of kinases (50 of 0.064 μM against PKN2, with ca. 17-fold selectivity over close homologue, PKN1.
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
-
, (2008/06/13)
Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
